Friday, October 07, 2022 2:23:19 PM
Recent ACHL News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/14/2024 12:04:13 PM
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates • GlobeNewswire Inc. • 08/14/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/05/2024 08:06:27 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 11:00:27 AM
- Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines • GlobeNewswire Inc. • 05/22/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/17/2024 09:15:57 PM
- Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement • GlobeNewswire Inc. • 05/17/2024 09:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 11:44:20 AM
- Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 04/04/2024 10:45:00 AM
- Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning • GlobeNewswire Inc. • 04/04/2024 10:30:00 AM
- Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference • GlobeNewswire Inc. • 02/05/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 06:14:13 PM
- Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction • GlobeNewswire Inc. • 12/18/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 09:36:37 PM
- Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 11/13/2023 09:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/01/2023 09:26:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/22/2023 08:42:59 PM
- Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement • GlobeNewswire Inc. • 09/22/2023 08:30:00 PM
- Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation • InvestorsHub NewsWire • 09/20/2023 12:45:00 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM